AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1-55. (canceled)

56. (currently amended) A preparation suitable for ~~the prevention and/or treatment of~~ treating a mammal having or at risk of developing dementia syndromes, cognitive degeneration or hearing loss, comprising the following fractions:

a) a long chain polyunsaturated fatty ~~acids~~ acid fraction comprising 200-2000 mg per daily dosage of at least one Ω-3 fatty acid selected from the group consisting of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) wherein fraction a) comprises at least 200 mg of DHA per daily dosage;

b) at least two different phospholipids selected from the group consisting of phosphatidylserine, phosphatidylinositol, phosphatidylcholine and phosphatidylethanolamine; and

c) at least one factor in methionine metabolism, selected from the group consisting of folic acid, vitamin B12, vitamin B6, magnesium and zinc.

57. (previously presented) The preparation according to claim 56, wherein fraction b) comprises phosphatidylcholine, phosphatidylethanolamine and phosphatidylserine.

58. (previously presented) The preparation according to claim 57, wherein the weight ratio of phosphatidylcholine and phosphatidylethanolamine to phosphatidylserine is in the range from 0.5:1 to 20:1.

59. (previously presented) The preparation according to claim 56, wherein the phospholipids are present in an amount of at least 0.2 g.

60. (previously presented) The preparation according to claim 56, wherein phosphatidylserine is present in an amount of at least 0.1 g.

61. (previously presented) The preparation according to claim 56, wherein fraction a) further comprises at least one member selected from the group consisting of linoleic acid and α-linolenic acid, and optionally one Ω-6 fatty acid selected from dihomogammalinolenic acid (DHGLA) and arachidonic acid (AA), and wherein the ratio of the total amount of EPA + DHA + DHGLA + AA to the total amount of linoleic acid and α-linolenic acid is above 0.4:1.

62. (previously presented) The preparation according to claim 56, further comprising d) at least one of a citrate or citric acid.

63. (previously presented) The preparation according to claim 56, further comprising e) huperzine A.

64. (canceled)

65. (previously presented) The preparation according to claim 56, wherein fraction c) further contains at least one member selected from the group consisting of S-adenosylmethionine, choline, betaine and copper.

66. (currently amended) The preparation according to claim 56, wherein ~~fraction c)~~ said preparation further comprises ~~zinc and~~ copper, ~~wherein~~ fraction c) comprises zinc, and the weight ratio of zinc to copper is between 5 and 12.

67. (previously presented) The preparation according to claim 56, which further contains f) at least one member selected from the group consisting of carnitine, vitamin B1, vitamin B5 and coenzyme Q10.

68. (previously presented) The preparation according to claim 56, which further contains g) at least one antioxidant selected from the group consisting of vitamin C, vitamin E, lipoic acid, selenium salts and carotenoids.

69. (previously presented) The preparation according to claim 56, which further contains h) an extract of ginkgo biloba.

70. (previously presented) The preparation according to claim 56, which comprises per daily dose:

at least 120 mg of long chain polyunsaturated fatty acids;

at least 200 mg phospholipids;

at least 200 µg folic acid; and

at least 500 mg citrate.

71. (previously presented) The preparation according to claim 70, which comprises per daily dose:

at least 20 mg eicosapentaenoic acid;

at least 50 mg docosahexaenoic acid;

at least 50 mg arachidonic acid;

at least 200 mg phospholipids;

at least 200 µg folic acid;

at least 100 mg magnesium;

at least 5 mg zinc;

at least 2 mg vitamin B6;

at least 2 µg vitamin B12; and

at least 1.0 g citrate.

72. (previously presented) The preparation according to claim 56, wherein said preparation is in the form of a nutritional supplement.

73. (currently amended) A method for treating ~~and/or preventing vascular disorders or secondary disorders associated therewith in a mammal in need thereof~~ a mammal having or at risk of developing dementia syndromes, cognitive degeneration or hearing loss, comprising administering to said mammal an

effective amount of a preparation comprising the following fractions:

a) a long chain polyunsaturated fatty ~~acids~~ acid fraction comprising 200-2000 mg per daily dosage of at least one Ω-3 fatty acid selected from the group consisting of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) wherein fraction a) comprises at least 200 mg of DHA per daily dosage;

b) at least two different phospholipids selected from the group consisting of phosphatidylserine, phosphatidylinositol, phosphatidylcholine and phosphatidylethanolamine; and

c) at least one factor in methionine metabolism, selected from the group consisting of folic acid, vitamin B12, vitamin B6, magnesium and zinc.

74. (canceled)

75. (canceled)

76. (new) The preparation according to claim 56, wherein fraction c) comprises at least 200 µg of folic acid, and at least 2 mg of vitamin B6 and/or at least 2 µg of vitamin B12 per daily dosage.

77. (new) The preparation according to claim 56, wherein the amount of phospholipids in fraction b) is at least 200 mg per daily dosage.

78. (new) The method according to claim 73, wherein fraction c) of said preparation comprises at least 200 µg of

folic acid, and at least 2 mg of vitamin B6 and/or at least 2 µg of vitamin B12 per daily dosage.

79. (new) The method according to claim 73, wherein the amount of phospholipids in said preparation in fraction b) is at least 200 mg per daily dosage.